[go: up one dir, main page]

WO2000061766A3 - Telomerase-specific cancer vaccine - Google Patents

Telomerase-specific cancer vaccine Download PDF

Info

Publication number
WO2000061766A3
WO2000061766A3 PCT/IB2000/000610 IB0000610W WO0061766A3 WO 2000061766 A3 WO2000061766 A3 WO 2000061766A3 IB 0000610 W IB0000610 W IB 0000610W WO 0061766 A3 WO0061766 A3 WO 0061766A3
Authority
WO
WIPO (PCT)
Prior art keywords
telomerase
cancer vaccine
specific cancer
useful
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2000/000610
Other languages
French (fr)
Other versions
WO2000061766A2 (en
Inventor
Babita Agrawal
Bryan Michael Longenecker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncothyreon Canada Inc
Original Assignee
Biomira Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomira Inc filed Critical Biomira Inc
Priority to EP00920996A priority Critical patent/EP1171612A2/en
Priority to JP2000611689A priority patent/JP2002541811A/en
Priority to CA002368967A priority patent/CA2368967A1/en
Priority to AU41394/00A priority patent/AU781376B2/en
Publication of WO2000061766A2 publication Critical patent/WO2000061766A2/en
Publication of WO2000061766A3 publication Critical patent/WO2000061766A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4246—Telomerase or [telomerase reverse transcriptase [TERT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/07—Nucleotidyltransferases (2.7.7)
    • C12Y207/07049—RNA-directed DNA polymerase (2.7.7.49), i.e. telomerase or reverse-transcriptase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Telomerase-specific T-cell antigens are provided, which are useful in generating T-cell responses against telomerase. Formulations of telomerase antigens as vaccines are useful in treating and preventing cancer, using in vivo or ex vivo techniques.
PCT/IB2000/000610 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine Ceased WO2000061766A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00920996A EP1171612A2 (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine
JP2000611689A JP2002541811A (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine
CA002368967A CA2368967A1 (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine
AU41394/00A AU781376B2 (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12853999P 1999-04-09 1999-04-09
US60/128,539 1999-04-09

Publications (2)

Publication Number Publication Date
WO2000061766A2 WO2000061766A2 (en) 2000-10-19
WO2000061766A3 true WO2000061766A3 (en) 2001-03-08

Family

ID=22435817

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2000/000610 Ceased WO2000061766A2 (en) 1999-04-09 2000-04-07 Telomerase-specific cancer vaccine

Country Status (5)

Country Link
EP (1) EP1171612A2 (en)
JP (1) JP2002541811A (en)
AU (1) AU781376B2 (en)
CA (1) CA2368967A1 (en)
WO (1) WO2000061766A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560437B2 (en) 1996-10-01 2009-07-14 Geron Corporation Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014593A2 (en) 1996-10-01 1998-04-09 Geron Corporation Human telomerase catalytic subunit
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
EP1257284A4 (en) * 2000-02-15 2005-12-21 Univ California A UNIVERSAL VACCINE AND A METHOD FOR THE TREATMENT OF CANCER WITH TELOMERASE REVERSE TRANSCRIPTASE
US7388071B2 (en) 2000-02-15 2008-06-17 The Regents Of The University Of California Composition and method for inducing and enhancing a telomerase reverse transcriptase-reactive cytotoxic T lymphocyte response
GB0031430D0 (en) * 2000-12-22 2001-02-07 Norsk Hydro As Polypeptides
EP1404298A2 (en) * 2001-06-25 2004-04-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem A method for preparation of vesicles loaded with biological material and different uses thereof
DE102006025146A1 (en) * 2006-05-30 2007-12-06 Charité - Universitätsmedizin Berlin Peptide that modulates proteasome activity, e.g. for disease treatment, comprises a human protein sequence
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
WO2014079464A1 (en) * 2012-11-21 2014-05-30 Sherif Salah Abdul Aziz A novel enzymes compositions for treatment of human immunodeficiency virus (hiv) infection

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014592A2 (en) * 1996-10-01 1998-04-09 Geron Corporation Telomerase reverse transcriptase
WO1998050527A1 (en) * 1997-05-08 1998-11-12 Biomira Inc. Method for generating activated t-cells and antigen-pulsed antigen-presenting cells
WO1999050392A1 (en) * 1998-03-31 1999-10-07 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
WO2000002581A1 (en) * 1998-07-08 2000-01-20 Norsk Hydro Asa Antigenic peptides derived from telomerase
WO2000025813A1 (en) * 1998-10-29 2000-05-11 Dana-Farber Cancer Institute CANCER IMMUNOTHERAPHY AND DIAGNOSIS USING UNIVERSAL TUMOR ASSOCIATED ANTIGENS, INCLUDING hTERT

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
40th Annual Meeting of the American Society of Hematology;Miami Beach, Florida, USA; December 4-8, 1998 *
GAGLIARDI M C ET AL: "Presentation of peptides by cultured monocytes or activated T cells allows specific priming of human cytotoxic T lymphocytes in vitro", INTERNATIONAL IMMUNOLOGY, vol. 7, 1995, pages 1741 - 1752, XP002078855, ISSN: 0953-8178 *
MINEV BORIS ET AL: "Cytotoxic T cell immunity against telomerase reverse transcriptase in humans.", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 9, 25 April 2000 (2000-04-25), pages 4796 - 4801, XP002155017, ISSN: 0027-8424 *
VONDERHEIDE R H ET AL: "Search for universal tumor antigens: Potential of the catalytic telomerase subunit.", BLOOD, vol. 92, no. 10 SUPPL. 1 PART 1-2, 15 November 1998 (1998-11-15), pages 500A, XP000971197, ISSN: 0006-4971 *
VONDERHEIDE R H ET AL: "THE TELOMERASE CATALYTIC SUBUNIT IS A WIDELY EXPRESSED TUMOR- ASSOCIATED ANTIGEN RECOGNIZED BY CYTOTOXIC T LYMPHOCYTES", IMMUNITY, vol. 10, no. 6, June 1999 (1999-06-01), pages 673 - 679, XP000890114, ISSN: 1074-7613 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7560437B2 (en) 1996-10-01 2009-07-14 Geron Corporation Nucleic acid compositions for eliciting an immune response against telomerase reverse transcriptase

Also Published As

Publication number Publication date
CA2368967A1 (en) 2000-10-19
AU781376B2 (en) 2005-05-19
AU4139400A (en) 2000-11-14
JP2002541811A (en) 2002-12-10
WO2000061766A2 (en) 2000-10-19
EP1171612A2 (en) 2002-01-16

Similar Documents

Publication Publication Date Title
WO2000061766A3 (en) Telomerase-specific cancer vaccine
WO1999033488A3 (en) Adjuvanted vaccine formulation
PL351893A1 (en) Vaccines
DE60012042D1 (en) ENTEPNEUMOVIRUS AND APPROPRIATE VACCINE
IL154913A0 (en) Composition comprising immunogenic microparticles
WO2002076404A3 (en) Fatty alcohol drug conjugates
WO2001000244A3 (en) METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES
WO2001000232A3 (en) Use of cpg as an adjuvant for hiv vaccine
PL373302A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
HUP0401753A3 (en) Antigen presenting cells, method for their preparation and their use for cancer vaccines
NZ514228A (en) Method of Expressing Antigens on the Surface of Antigen Presenting Cells by Photochemical Internalisation
WO2004045529A3 (en) West nile virus vaccine
WO2001062283A3 (en) Mucosal adjuvant formulation
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
WO2000067788A3 (en) Use of soluble costimulatory molecules to enhance immune responses
WO2002034773A3 (en) Streptococcal genes
WO2003094828A3 (en) Cancer vaccines and methods of using the same
GB2370772B (en) Acellular immunogenic compositions and acellular vaccine compositions against bacillus anthracis
MXPA02012249A (en) Peptides, compositions and methods for the treatment of burkholderia cepacia.
AU2001245295A1 (en) Methods and compositions for the identification, assessment, prevention and therapy of human cancers
WO2000053231A3 (en) Fatty acid-anticancer conjugates and uses thereof
IL144845A0 (en) Vaccines and gene therapy compositions and methods of making and using the same
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
AU1815899A (en) Method and composition to enhance the efficacy of a vaccine using chemokines
MY127452A (en) Vaccines.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2368967

Country of ref document: CA

Ref country code: CA

Ref document number: 2368967

Kind code of ref document: A

Format of ref document f/p: F

Ref country code: JP

Ref document number: 2000 611689

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000920996

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000920996

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 09958398

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2000920996

Country of ref document: EP